Cencora, Inc. (COR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
COR Revenue Growth
Revenue Breakdown (FY 2021)
COR's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
By Geography
COR Revenue Analysis (2014–2025)
As of May 6, 2026, Cencora, Inc. (COR) generated trailing twelve-month (TTM) revenue of $325.78 billion, reflecting solid growth of +5.5% year-over-year. The most recent quarter (Q1 2026) recorded $85.93 billion in revenue, up 2.6% sequentially.
Looking at the longer-term picture, COR's 5-year compound annual growth rate (CAGR) stands at +11.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $321.33 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows COR's business is primarily driven by Pharmaceutical Distribution (100%). With over half of revenue concentrated in Pharmaceutical Distribution, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MCK (+15.5% YoY), CAH (+12.8% YoY), and OMI (-41.0% YoY), COR has underperformed the peer group in terms of revenue growth. Compare COR vs MCK →
COR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CORCurrent | $325.8B | +5.5% | +11.1% | 1.1% | |
 MCK | $359.1B | +15.5% | +9.2% | 1.2% | |
 CAH | $222.6B | +12.8% | +7.8% | 1.0% | |
 OMI | $2.8B | -41.0% | -20.1% | 1.0% | |
 HSIC | $13.2B | +4.0% | +5.4% | 5.7% | |
 CVS | $402.1B | +7.8% | +8.4% | 2.6% |
COR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $321.33B | +9.3% | $10.14B | 3.2% | $3.65B | 1.1% |
| 2024 | $293.96B | +12.1% | $8.70B | 3.0% | $3.04B | 1.0% |
| 2023 | $262.17B | +9.9% | $7.76B | 3.0% | $2.45B | 0.9% |
| 2022 | $238.59B | +11.5% | $7.60B | 3.2% | $2.75B | 1.2% |
| 2021 | $213.99B | +12.7% | $6.27B | 2.9% | $2.68B | 1.3% |
| 2020 | $189.89B | +5.7% | $4.79B | 2.5% | $2.02B | 1.1% |
| 2019 | $179.59B | +6.9% | $4.53B | 2.5% | $1.87B | 1.0% |
| 2018 | $167.94B | +9.7% | $4.11B | 2.4% | $1.65B | 1.0% |
| 2017 | $153.14B | +4.3% | $4.15B | 2.7% | $2.02B | 1.3% |
| 2016 | $146.85B | +8.0% | $3.77B | 2.6% | $1.68B | 1.1% |
Full COR Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See COR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCOR — Frequently Asked Questions
Quick answers to the most common questions about buying COR stock.
Is COR's revenue growth accelerating or slowing?
COR maintains +5.5% revenue growth, in line with its 5-year CAGR of +11.1%. TTM revenue stands at $325.8B. Growth rate remains consistent with historical average.
What is COR's long-term revenue growth rate?
Cencora, Inc.'s 5-year revenue CAGR of +11.1% reflects the sustained expansion pattern. Current YoY growth of +5.5% is near this long-term average.
How is COR's revenue distributed by segment?
COR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.